![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BTG2 |
Gene summary for BTG2 |
![]() |
Gene information | Species | Human | Gene symbol | BTG2 | Gene ID | 7832 |
Gene name | BTG anti-proliferation factor 2 | |
Gene Alias | APRO1 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P78543 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7832 | BTG2 | GSM4909282 | Human | Breast | IDC | 1.00e-51 | 1.09e+00 | -0.0288 |
7832 | BTG2 | GSM4909286 | Human | Breast | IDC | 4.61e-03 | -1.98e-01 | 0.1081 |
7832 | BTG2 | GSM4909290 | Human | Breast | IDC | 1.63e-10 | -4.38e-01 | 0.2096 |
7832 | BTG2 | GSM4909293 | Human | Breast | IDC | 1.41e-04 | 3.93e-01 | 0.1581 |
7832 | BTG2 | GSM4909296 | Human | Breast | IDC | 6.89e-06 | -3.06e-01 | 0.1524 |
7832 | BTG2 | GSM4909297 | Human | Breast | IDC | 2.71e-10 | 3.25e-01 | 0.1517 |
7832 | BTG2 | GSM4909298 | Human | Breast | IDC | 1.41e-14 | 6.32e-01 | 0.1551 |
7832 | BTG2 | GSM4909299 | Human | Breast | IDC | 9.89e-15 | 5.71e-01 | 0.035 |
7832 | BTG2 | GSM4909300 | Human | Breast | IDC | 3.61e-02 | 4.77e-01 | 0.0334 |
7832 | BTG2 | GSM4909301 | Human | Breast | IDC | 1.02e-25 | 7.35e-01 | 0.1577 |
7832 | BTG2 | GSM4909303 | Human | Breast | IDC | 1.88e-09 | 8.03e-01 | 0.0438 |
7832 | BTG2 | GSM4909305 | Human | Breast | IDC | 3.40e-06 | 4.44e-01 | 0.0436 |
7832 | BTG2 | GSM4909306 | Human | Breast | IDC | 2.22e-09 | 4.00e-01 | 0.1564 |
7832 | BTG2 | GSM4909308 | Human | Breast | IDC | 8.37e-65 | 1.20e+00 | 0.158 |
7832 | BTG2 | GSM4909311 | Human | Breast | IDC | 3.11e-13 | -7.53e-02 | 0.1534 |
7832 | BTG2 | GSM4909312 | Human | Breast | IDC | 7.28e-39 | 9.42e-01 | 0.1552 |
7832 | BTG2 | GSM4909313 | Human | Breast | IDC | 3.42e-40 | 1.10e+00 | 0.0391 |
7832 | BTG2 | GSM4909315 | Human | Breast | IDC | 3.14e-07 | -3.70e-01 | 0.21 |
7832 | BTG2 | GSM4909319 | Human | Breast | IDC | 3.08e-21 | 2.38e-01 | 0.1563 |
7832 | BTG2 | GSM4909321 | Human | Breast | IDC | 3.81e-26 | 7.90e-01 | 0.1559 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
GO:190331324 | Thyroid | ATC | positive regulation of mRNA metabolic process | 75/6293 | 118/18723 | 2.57e-11 | 8.84e-10 | 75 |
GO:004348725 | Thyroid | ATC | regulation of RNA stability | 97/6293 | 170/18723 | 2.68e-10 | 7.70e-09 | 97 |
GO:006101325 | Thyroid | ATC | regulation of mRNA catabolic process | 95/6293 | 166/18723 | 3.27e-10 | 9.16e-09 | 95 |
GO:004348826 | Thyroid | ATC | regulation of mRNA stability | 90/6293 | 158/18723 | 1.31e-09 | 3.30e-08 | 90 |
GO:0070997210 | Thyroid | ATC | neuron death | 176/6293 | 361/18723 | 1.43e-09 | 3.57e-08 | 176 |
GO:190121428 | Thyroid | ATC | regulation of neuron death | 156/6293 | 319/18723 | 9.30e-09 | 1.96e-07 | 156 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:004343428 | Thyroid | ATC | response to peptide hormone | 192/6293 | 414/18723 | 3.63e-08 | 6.70e-07 | 192 |
GO:0061157110 | Thyroid | ATC | mRNA destabilization | 52/6293 | 84/18723 | 1.01e-07 | 1.70e-06 | 52 |
GO:0061014110 | Thyroid | ATC | positive regulation of mRNA catabolic process | 53/6293 | 87/18723 | 1.63e-07 | 2.61e-06 | 53 |
GO:004593015 | Thyroid | ATC | negative regulation of mitotic cell cycle | 117/6293 | 235/18723 | 1.93e-07 | 3.05e-06 | 117 |
GO:0050779110 | Thyroid | ATC | RNA destabilization | 53/6293 | 88/18723 | 2.75e-07 | 4.20e-06 | 53 |
GO:005140227 | Thyroid | ATC | neuron apoptotic process | 120/6293 | 246/18723 | 5.41e-07 | 7.75e-06 | 120 |
GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
GO:004352323 | Thyroid | ATC | regulation of neuron apoptotic process | 104/6293 | 212/18723 | 2.16e-06 | 2.58e-05 | 104 |
GO:0000288110 | Thyroid | ATC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 36/6293 | 56/18723 | 2.57e-06 | 3.00e-05 | 36 |
GO:000961225 | Thyroid | ATC | response to mechanical stimulus | 105/6293 | 216/18723 | 3.29e-06 | 3.70e-05 | 105 |
GO:001470622 | Thyroid | ATC | striated muscle tissue development | 168/6293 | 384/18723 | 1.91e-05 | 1.73e-04 | 168 |
GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030186 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301811 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301821 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa0301831 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa030184 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa030185 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa030187 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
hsa0301812 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301861 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa0301871 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BTG2 | SNV | Missense_Mutation | rs752692832 | c.335N>A | p.Arg112His | p.R112H | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BTG2 | SNV | Missense_Mutation | novel | c.403C>A | p.Leu135Ile | p.L135I | P78543 | protein_coding | tolerated(1) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BTG2 | SNV | Missense_Mutation | novel | c.206N>A | p.Arg69His | p.R69H | P78543 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BTG2 | SNV | Missense_Mutation | novel | c.450N>T | p.Lys150Asn | p.K150N | P78543 | protein_coding | tolerated(0.05) | benign(0.082) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BTG2 | SNV | Missense_Mutation | rs752692832 | c.335G>A | p.Arg112His | p.R112H | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
BTG2 | SNV | Missense_Mutation | c.205N>G | p.Arg69Gly | p.R69G | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
BTG2 | SNV | Missense_Mutation | c.196C>G | p.Arg66Gly | p.R66G | P78543 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-86-6562-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD | |
BTG2 | SNV | Missense_Mutation | rs757308128 | c.337N>T | p.Ile113Phe | p.I113F | P78543 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-MP-A4TK-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
BTG2 | SNV | Missense_Mutation | novel | c.310N>A | p.Val104Met | p.V104M | P78543 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CN-4730-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BTG2 | insertion | Frame_Shift_Ins | novel | c.18_19insCA | p.Thr7GlnfsTer19 | p.T7Qfs*19 | P78543 | protein_coding | TCGA-BA-6873-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |